Please login to the form below
Aliqopa
This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.
FDA clears Novartis’ new breast cancer drug Piqray
Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and Verastem’s Copiktra (duvelisib) – but so far they have been unable to
Latest news
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently
-
Novartis considers filings for PI3K drug in breast cancer
years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers.
-
Bayer bags speedy US approval for lymphoma drug Aliqopa
The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Aliqopa (copanlisib) has been given a conditional green light as a third-line treatment for patients with relapsed
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Client Services Director- Flexible Working
-
Negotiable
-
Senior Medical Writer
-
Competitive salary plus benefits
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Events Executive
-
DOE
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
GCI Health
GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
